

Investors' Meeting for the Current Priority Management Issues and Business Strategy

September 25, 2025

Nobuaki Mito – President



Section
01

Introduction

4

Section
02

FY 2025-2027 Progress on the Corporate Business Plan

Basic
direction
01

Upgrade business portfolio with new growth strategy

8

- (1) Winning businesses rooted in organic synthesis technology
- (2) Cultivating new growth businesses

8
21

Basic
direction
02

Build greater resilience by executing continued structural reforms

25

Basic
direction
03

Improve financial and capital efficiency

31

Section
03

Epilogue

34

- In the half-year since becoming CEO, I have striven to **focus on businesses where we can win and strengthen employee engagement.**
- Across the business portfolio, we have upgraded and strengthened competitiveness across segments with a **focus on winning businesses rooted in our strength in organic synthesis technologies.**
- We made solid progress **reorganizing P&P businesses inside and outside Japan, including PetroRabigh and our business integration with Prime Polymer.**
- Regarding Sumitomo Pharma,
 - ✓ In the small molecule drug business, while **promoting the expansion of three key products and the development of two oncology drugs**, the company is **considering its medium- to long-term direction.**
 - ✓ The regenerative medicine/cell therapy business is being **developed as a new growth area for the group.**
- We strengthened investment management processes to **redouble efforts toward ROIC-oriented management** and built decision-making and monitoring regimes capable of responding with agility to environmental changes.



Section

01

Introduction

My aims at CEO


Play where we can win

Focus on businesses where we enjoy a technological edge and build a more resilient portfolio. Enhance capital profitability and recover the market's trust.

Strengthen employee engagement

Remove the "elephant in the room." Foster a startup mentality and lead the organization to repeatedly take full swings at the challenges we face.

Our winning businesses rooted in our strengths in organic synthesis technology can drive us toward growth.



Slogan

Leap Beyond

~Return to a growth trajectory~

Vision for this plan

Return to a growth trajectory and show the way toward further growth

FY2027
Financial targets

Core Operating
Income
200 bn. yen

ROE
8%

ROIC
6%

D/E ratio
Approx. 0.8X

Basic
direction
01

Upgrade business portfolio with new growth strategy

Basic
direction
03

Improve financial and capital efficiency

Basic
direction
05

Strengthen management base supporting new growth strategy

Basic
direction
02

Build greater resilience by executing continued structural reforms

Basic
direction
04

R&D strategy based on 3 X's

Talent

DX

Governance



Section

02

Basic
direction
01


FY 2025-2027

Progress on the Corporate Business Plan

Upgrade business portfolio with new growth strategy

- (1) Winning businesses rooted in organic synthesis technology
- (2) Cultivating new growth businesses

A business portfolio that is completely aligned with base technologies.
In each segment, focus on **businesses where we can win.**




3 Blockbuster candidates driving growth in the chemicals business

INDIFLIN®

- Expand product portfolio (mixtures, etc.)
- Develop new business opportunities (countries, crops indicated, applications)
- Launch in the UK and EU nations in 2026 and beyond

Tens of billions of yen just a few years from launch
By 2030:

Sales of several tens of billions of yen




Rapidicil®

- Advance registration in countries in North and South America. Expand product lineup by developing mixture products.
- Build next-generation weed controls for use with PPO-tolerant crops
- Launched in Argentina. Register in US in 2026 and Brazil in 2027.

By 2030:

Sales of several tens of billions of yen




Pavecto®

- Advance registration in South America and Europe. Expand product lineup by developing mixture products.
- A unique QoI* fungicide that is effective against bugs that exhibit resistance to existing QoIs
- Register in Brazil and Europe in the late 2020s

By the mid-2030s:

Sales of several tens of billions of yen




* QoI : Quinone outside Inhibitors

Winning in Agro & Life Solutions

INDIFLIN® Expand product and indication opportunities to provide solutions that meet user needs

PLCM* through expansion of a diverse product portfolio

- ✓ Advance new product development leveraging a global R&D network
- ✓ Execute PLCM to differentiate against rivals and maximize sales and profits across the product's entire life cycle



* PLCM : Product Life Cycle Management

Expand geographies, crops, and applications

- ✓ Search for additional INDIFLIN® indication opportunities
- ✓ Recently launched in Australia and India



India: rice (2025)



Australia potatoes and bananas (2024)

US and Japan:
Also applicable
to specialty crops

Blockbuster in
soybean rust

Rapidicil®

Increase geographic coverage in major markets and expand business with indication for next-generation weed control systems

Strengths

- ✓ Fast-acting non-selective herbicide
- ✓ Exhibits efficacy in low doses
- ✓ Suited for no-till farming


Registration schedule

- ✓ Argentina: Launched EMPERA® in FY 2024
- ✓ US: Launch in 2026
- ✓ Brazil: Launch in 2027

Global herbicide market (2023)

(Source: Agbiolnvestor)

Total : 31 bn. USD



How it is used

Today

Preplant Burndown (PPBD/before planting)



Top photo shows before, bottom photo shows 3 days after Rapidicil® treatment.

Eliminate weeds before planting the crop

Suitable for no-till farming, which also helps preserve soil


Contributes to **regenerative agriculture**

2030 and beyond


Over the Top (OTT/applied over the top of a crop that is already growing)

Build next-generation weed control systems by combining with Rapidicil-resistant crops

Expect sharp sales growth given Rapidicil's suitability toward both PPBD and OTT



Sustainable topline growth through indication for next-generation weed control systems



Biorationals and botanicals strategy

Business Environment

- Advance change from modern to regenerative agriculture

➔ Increasingly stringent regulatory requirements and growing demand for sustainable products

Our strengths

- **Product development capabilities :** PLCM based on customer needs (new applications, products, and mixtures)
- **Manufacturing regime and quality control :** One of the world's leading fermentation plants for agricultural materials and a robust natural pyrethrin supply regime
- **Brand power :** Trust built upon experience of 60 years in biorationals and 120 years in botanicals
- **Market share :** Top-class market share in the premium segment

Priority initiatives aimed at accelerating growth

- **Expand Brazil business**

- ✓ Stimulate demand with dedicated biorationals organization
- ✓ Strengthen product deployment for soybeans and sugar

➔ **Grow beyond a \$100M business in South America**

- **Expand biostimulants business**

- ✓ Expand sales inside and outside the US via integrated operations with FBSciences


- **Strengthen R&D capabilities**

- ✓ Place synthetic biology team at US biorationals research institute
- ✓ Establish group dedicated to biorationals research in Japan, too
- ✓ **40+** product development projects under way


- **Further enhance botanicals portfolio and accelerate sales expansion**

- ✓ In the US, acquire registrations in non-food applications of new botanical insecticides and promote development of synergists
- ✓ Expand sales of botanicals in crop protection, pest control and other areas

Expand business scale by FY 2030:



- Semiconductor materials (Photoresist)** proprietary cutting-edge resists based on our new platform development and expand share



Alkaline development with negative resist (ArF immersion)

- ✓ Change some of the ArF immersion resist development steps to an alkaline development method to reduce costs and environmental impact
- ✓ Advance global top-class ArF immersion resist technology and actively propose to customers

FY 2026

Osaka: Introduce cutting-edge semiconductor photoresist to a lithography tool

Strengths

Alkaline development

Process cost down and
Reduction of
environmental impact

Negative type

Better for forming
specific patterns

Organic molecule resist (High NA EUV)

- ✓ Design and mass-produce resist materials at molecular size to support ultimate miniaturization of semiconductors
- ✓ Concentrate R&D resources and accelerate development of next-generation platform, and currently conduct proof-of-concept testing at leading companies

Strengths

Metal-free

Affinity with existing
processes

Molecule: <1nm

Achieves miniaturization

Contrast

Target **20%** share by volume in cutting-edge resist

Winning in ICT & Mobility Solutions

Semiconductor materials (High-purity chemicals)

Establish world-class business scale with supply capabilities built from upfront investments
Strengthen our world-class process and analysis technologies supporting cutting-edge semiconductor technology



Dongwoo Fine-Chem Iksan Plant



Dongwoo Fine-Chem Iksan Research Laboratory

Add capacity at existing plant
Secure land for new plant
Increase staff in production technology and development
Install clean room for cutting-edge materials
and decide to expand process validation line

South Korea

NEW

US

Texas site
Begin mass production in 2025

Study building additional production capacity in the United States



Sumika Semiconductor Materials Texas Inc.

Support cutting-edge quality
Add manufacturing line for high-purity sulfuric acid

Japan


China

Changzhou
Xi'an

NEW

India

Build base for business



Display materials

Quickly realize optimal molecular design based on our strengths in organic synthesis technology

Polarizing film fo OLED

Business Environment
Smartphone market needs
Thin profile, unique shapes
Tablet and notebook markets
Ramping up shift to OLED

- Contribute to high-quality black expression leveraging our proprietary **liquid crystal compound synthesis technology**
- **Fully integrated in-house design** from compound to film

Leverage our proprietary technologies to keep No.1 position

Automotive polarizers

Business Environment
Moving toward larger sizes[※]
Growing demand for materials that support higher functionality
[※] By 2030, displays to double in size compared to today

- Design **high-durability polarizers** that meet strict in-vehicle environmental standards
- Support **wider view angles** made necessary by larger displays

Expand share in the high-end market by further enhancing durability

Foldable panel components (CoE)

Business Environment
Mass production started in some models
Thinner, richer colors, and lower power consumption

- Develop color materials that contribute to **higher brightness and color purity**
- **Design color materials at the molecular level** based on organic synthesis technology developed in other businesses

Expand share through further improvement of product characteristics and a broader product portfolio

Winning in Advanced Medical Solutions

Deploy a winning CDMO strategy leveraging our strengths

Drug Discovery modality

Where we can win
Organic synthesis technology and
comprehensive support capabilities

■ Small molecule

Shifting to more advanced

Differentiation leveraging organic synthesis
technology and comprehensive support capabilities

□ Biopharmaceuticals
(antibody drugs, etc.)

■ Gene therapy

■ Regenerative medicine/cell therapy

Collaborate with customers and support
modality deployment

Advanced small molecule APIs CDMO

- ✓ Leverage our strength in **comprehensive support capabilities** to win more contracts
- ✓ Leverage our **advanced organic synthesis technologies** to strengthen support of new technologies and **difficult projects**
(such as PROTAC*¹ and ADC*²)

*¹ Proteolysis targeting chimera *² Antibody-Drug Conjugate

Where we will NOT play

- ✓ Require large-scale capital investments
- ✓ Fermentation and enzymes (≠ organic synthesis)

Oligonucleotide CDMO

- ✓ Refine our synthesis technologies in **high-purity long-chain nucleotides** and expand the business

Regenerative medicine/cell CDMO

- ✓ Quickly expand business performance leveraging our **strength as the front runner in the commercialization of iPS cells**

Winning in Advanced Medical Solutions

Expand advanced small molecule APIs CDMO business leveraging our comprehensive support capabilities

What is our "advanced" small molecule APIs CDMO?

- ✓ Recent small molecule APIs have relatively large molecular weights and complex structures
- ✓ Based on our advanced organic synthesis technologies, we have been winning contracts to manufacture difficult-to-make "advanced" small molecule APIs
- ✓ We support both PROTAC, which has a novel mechanism of action, and ADC, which combines antibodies with small molecule APIs

Strengths

✓ Comprehensive support capabilities

Footprint of 3 sites
(BCP and flexibility)Quality assurance
regime

Supply chain

R&D
infrastructure


✓ Advanced organic synthesis technologies



Small molecule API plant (Oita)
launched in October 2024


Small molecule APIs market size

(Source: Cabinet Secretariat)



(Source: Cabinet Secretariat)

Small molecule APIs as a % of all modalities(2024)



- ✓ Small molecule APIs to maintain strength with a sizable market
- ✓ Future demand to be robust for CDMOs that possess advanced manufacturing technologies

Our actions

- Strengthen orders from Japanese pharma that require our comprehensive support capabilities
- Further enhance our manufacturing technologies rooted in organic synthesis and strengthen our support of "advanced" small molecule projects


Leverage new site to accelerate business deployment of medical oligonucleotide CDMO

Oligonucleotide

- ✓ Nucleic acids necessary for cutting-edge genome editing therapies includes gRNA with a length of more than 100mer--far longer than general nucleic acid drugs

What is gRNA?


Guides the enzyme capable of cutting and editing genes to the correct target gene to be cut and edited



Strengths

- ✓ **Manufacturing technology for high-purity medical oligonucleotides**
- ✓ **Multiple production sites**
- ✓ **Sales and development support sites**

Market size of in vivo gene therapies



- ✓ The global gene therapy market is expected to grow substantially
- ✓ US bioventures are increasingly entering the space, growing demand for high-purity gRNA and expanding business opportunities

Our actions

- Created development support site (SC-AMSA) in the US to strengthen customer support
- Accelerate standardization of high purity, high quality and analysis technologies for gRNA that we are uniquely equipped to deliver

Expand licensing and catalysts business by capturing demand from growth in emerging countries while we contribute to global Green Transformation (GX) with next-generation technologies

2025

2030


2035

Leverage existing technological assets to expand our licensing and catalysts business

Rapidly ramp up next-generation technologies

Maximize existing technological assets

- Our proprietary high-performance catalysts support many of our process technologies, such as hydrochloric acid oxidation process and PO-only process. We will continue to add to our lineup.
- The presence of our technologies in global markets has grown through collaborations with KBR and Lummus, which began in 2024.



Develop next-generation technologies

- Advance the development of many GX technologies, such as ETEP, which makes propylene directly from ethanol
- Accelerate the deployment into society of our PMMA chemical recycling technology through our licensing collaboration with Lummus
- We aim to rapidly ramp up our contributions through optimal partnerships tailored to specific objectives.



ETEP pilot plant exterior



Section

02

Basic
direction
01

FY 2025-2027

Progress on the Corporate Business Plan

Upgrade business portfolio with new growth strategy

- (1) Winning businesses rooted in organic synthesis technology
- (2) Cultivating new growth businesses




See more on page 30

Small molecule drugs (drug discovery)

Regenerative medicine/cell therapy (R&D/CDMO)

As a group, focus on businesses where we can win

Integrate efforts across the group to expand the regenerative medicine/cell therapy business



How are we uniquely equipped to win?

- ✓ One of the origins of the business dates back to 2003 and our continued research in ES cells as part of our chemicals safety evaluation
- ✓ Since the 1990s, we have emphasized neural regeneration research and led the world in regenerative medicine/cell therapy using iPS cells
- ✓ We fused our commercialization and analysis technologies and quality management know-how with technologies and learnings developed over many years in regenerative medicine/cell therapy

Why can we win here?

- ✓ R&D: High barrier to entry from generics. Moderate patent cliff.
- ✓ CDMO: Limited capital investment relative to antibody drugs


Regenerative medicine/cell therapy (R&D)


RACTHERA

Aiming for greater groupwide contribution to treatment using regenerative medicine/cell therapy

What is an iPS cell?


- ✓ Nearly **limitless reproduction** under culturing conditions
- ✓ Can be **split into nearly all cells**
⇒ Means to resolve donor shortages and ethical concerns around transplant treatments




Regenerative medicine/cell therapy market

Global market forecast for regenerative medicine/cell therapies
(organ and cell transplants)

(Source: Japan Agency for Medical Research and Development)



Our Parkinson's disease therapies



- ✓ **Filed NDA with hope to gain approval before the end of FY 2025** in Japan to launch the world's first therapy derived from iPS cells
- ✓ In the US, performed transplant in first patient in investigator-initiated study
- ✓ Poised to **grow into a blockbuster (100 bn. yen in sales)** in the 2030s

Regenerative medicine/cell therapy (CDMO)


S - RACMO

Expand CDMO business with a focus on regenerative medicine/cell therapies

Business Performance Trends

In an environment where it is challenging to acquire stable revenue opportunities:


4 consecutive years of profitability

Strengths

- ✓ **Know-how as the front runner in commercializing iPS cells**
- ✓ **Track record commercially manufacturing cells**
- ✓ **CDMO synergies**

✓ Horizontally deploy our established CDMO business base

✓ Deploy our proprietary high-purity gRNA technology across the regenerative medicine /cell therapies business



Regenerative medicine/cell therapy

1. **SMaRT** (completed March 2018) 2. **FORCE**(completed December 2021)

• World's first iPS product manufacturing facility

• Running at full capacity on robust demand

NEW

3. **CRAFT** (completed July 2025)

• Already received many inquiries
• Plan to launch soon



NEW

Build 4th plant and solidify business expansion

- ✓ Capital investment is limited relative to bio-CDMO

Investment: **15 bn. yen**  Several hundred bn.

Leverage METI subsidies to further shrink investment amount



Section

02

Basic
direction

02

FY 2025-2027

Progress on the Corporate Business Plan

**Build greater resilience
by executing continued structural reforms**

Financial improvement plan

FY2024

- Wrote-off loans totaling \$1,500m from both SCC and Aramco *1 ▶ Mitigating PRC interest burden

*1 Aramco wrote-off the loans of \$500m in FY2024 and \$250m in FY2025.

FY2025

- SCC completes sale of approximately 22.5% of PRC to Aramco for \$702m ▶ Our ownership stake will be 15% from Oct, 2025
- Including the proceeds from the sale, a total of \$1,404m is expected to be contributed to PRC *2 ▶ Further mitigating PRC interest burden

*2 The first issuance of a different class of ordinary shares by a public company in Saudi Arabia

Plan to strengthen earnings power

FY2025

- Strengthen earnings power (**Short-term**) ▶ Gradual contribution to earnings starting from 2025
 - ✓ Capacity increase through de-bottlenecking of ethane cracker and HOFCC (ethylene: 105%, propylene: 109%)
 - ✓ Strengthen feedstock competitiveness by changing crude oil types, and increase margins in refined products (producing low-sulfur diesel, upgrading light naphtha to gasoline), etc.


FY2026+

- Strengthen earnings power (**Mid- to long-term**)
 - ▶ Continuing to consider fundamental measures to improve earnings, including upgrades to refinery assets

Japan P&P reorganization

Strengthen domestic polyolefin business competitiveness with integration into domestic leader Prime Polymer

Illustration of business integration
(beginning April 2026)



Toward a **more resilient** and **essential** business

Integration overview

- ✓ Integrate our domestic PP* and LLDPE businesses into PRM
- *Including our domestic compound business

Benefits of integration

- ✓ Reduces PRM's costs by more than 8 bn. yen per year
- ✓ Accelerates development of high-performance environmentally friendly products

Sumitomo Chemical's aim

- ✓ Establish a competitive edge through integration with domestic leader PRM
- ✓ Also seek upstream synergies through ties with both partners

Direction for P&P businesses

Action plan to achieve that direction

Direction

Concentrate on high value-added products and phase down commodity P&P businesses
 Strengthen ties and reorganization with P&P peers and accelerate shift to solutions businesses that reduce environmental impacts

Action plan execution status

Japan

Optimized operations at Keiyo Ethylene

→ Get to 100% utilization rate for the time being

Business integration with Prime Polymer

→ Strengthen long-term competitiveness through integration with leading player

Develop technologies that reduce environmental impact (Green Investment Fund)

Overseas

Plan to improve financial standing at PetroRabigh

→ Shrank holding about 60% through sale of shares

Structural Reforms in Singapore

MMA

Shuttered two lines and concentrated on high-earning fields. Achieved profitability.

Upstream

Continue to study optimal structure at PCS

Downstream

Sold CPSC. Expand sales of high value-added grades at TPC.

Direction for P&P businesses

~2015年

2022年

2024年

2027年

2030年~

Phase 1

Restructure Chiba Works
to strengthen
competitiveness

Closed ethylene plant

Exited SM Cut PO capacity

Exited polystyrene business

Sold PVC business

Phase 2

Structural Reforms
through corporate ties and
production optimization

Optimized operations at Keiyo Ethylene

Integrated business into Prime Polymer

Sold ABS business Exited synthetic rubber

Exited caprolactam

Plan to improve financial standing
at Petro Rabigh

Restructured Singapore business

Accelerated development of technologies
that reduce environmental impact

Phase 3

Pivot to solutions
businesses that reduce
environmental impact

Deploy into society technologies that
reduce environmental impact

Converted to feedstock for GHG
reduction.

Established GX Solutions Business



Direction



Concentrate on high value-added products and phase down commodity P&P businesses
Strengthen ties and reorganization with P&P peers and accelerate shift to solutions
businesses that reduce environmental impacts



Sumitomo Pharma

Small molecule drugs (drug discovery)

Focusing on expanding sales of 3 key products and the early launch of 2 oncology products



Launch targets for 2 oncology products

enzomenib FY 2027

nuvisertib FY 2028

Regenerative medicine/cell therapy (R&D/CDMO)

Our direction for small molecule drugs (drug discovery)

- ✓ Moving forward, need to protect against new LOE, etc.
- ✓ Limited synergies in small molecule drugs (drug discovery)
- ✓ Over the near-term, stabilize earnings while pursuing all possible options from a medium- to long-term perspective, such as searching for the best partner

Indicate direction during the term of this Corporate Business Plan



Section

02

Basic
direction
03

FY 2025-2027

Progress on the Corporate Business Plan

Improve financial and capital efficiency

Thoroughly re-implement ROIC-oriented management

Strengthen investment management processes to enhance probability of investment success

Investment and business decision-making rooted
in thorough risk management

Data-driven

Quantify risk based on probability distributions across a diverse range of scenarios



Quantitatively visualize risk, seize opportunities, and make decisions with agility

Objective

Place import on third-party expert opinions about market trends and competitive advantages



Secure validity by supplementing internal knowledge with objective viewpoints

Monitoring for flexible
strategy operations

Agile

Adopt continuing milestone KPIs that capture early warning signs




Advance strategies with flexibility and speed and pre-empt environmental changes

Enhance ROIC by maximizing investment efficiency

Shareholder returns

Dividend payout ratio during the period under the new plan is expected to be over 30%. Aim for 24 yen/share or more per year early in the future.



29.9	26.9	30.5	89.9	53.3	24.2	421.2	—	38.2	49.1	Dividend payout ratio (%)
1.24	1.09	0.84	0.57	0.92	0.75	0.62	0.57	0.66		PBR




Section

03

Epilogue

Continue to improve capital efficiency and enhance enterprise value over the medium to long term



Upgrade
business portfolio

Restructuring

- 3 blockbuster chemical crop protection products
 - World-class semiconductor and display materials business
 - Strong CDMO business portfolio in advanced small molecule APIs, gene therapy, and regenerative medicine/cell therapy
 - World-leading regenerative medicine/cell therapy
 - Technologies that reduce environmental impact ready to be deployed into society
-
- The P&P restructuring has made significant progress.
 - Powerful recovery in small molecule drugs (drug discovery)

Cautionary Statement

Statements made in this document with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.